FAL1: A critical oncogenic long non-coding RNA in human cancers

• Published in: Life sciences (1973) Vol. 236; p. 116918
• Main Authors: Lv, Xiurui, Li, Yang, Li, Yuhan, Li, Hongxing, Zhou, Lingling, Wang, Binyu, Zhi, Zhengke, Tang, Weibing
• Format: Journal Article
• Language: English
• Published: New York Elsevier Inc 01.11.2019; Elsevier BV
• Subjects: Cancer; Cell proliferation; Chromosome 1; Chromosomes; Diagnostic software; Diagnostic systems; eRNA; FAL1; lncRNA; Metastases; Molecular modelling; Non-coding RNA; Nucleotides; Review; Therapeutic applications; Tumorigenesis; FAL1; lncRNA; Review; eRNA; Cancer
• ISSN: 0024-3205; 1879-0631
• DOI: 10.1016/j.lfs.2019.116918

Long noncoding RNAs (lncRNAs) are characterized as a group of endogenous RNAs that are more than 200 nucleotides in length and have no protein-encoding function. More and more evidence indicates that lncRNAs play vital roles in various human diseases, especially in tumorigenesis. Focally amplified lncRNA on chromosome 1 (FAL1), a novel lncRNA with enhancer-like activity, has been identified as an oncogene in multiple cancers and high expression level of FAL1 is usually associated with poor prognosis. Dysregulation of FAL1 has been shown to promote the proliferation and metastasis of cancer cells. In the present review, we summarized and illustrated the functions and underlying molecular mechanisms of FAL1 in the occurrence and development of different cancers and other diseases. FAL1 has the potential to appear as a feasible diagnostic and prognostic tool and new therapeutic target for cancer patients though further investigation is needed so as to accelerate clinical application.